Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options

Journal of Human Hypertension volume 24, pages 1–8 (2010)Cite this article

Abstract

Oxidative stress has been increasingly linked to the high incidence of cardiovascular events in patients with chronic kidney disease (CKD), especially as traditional cardiovascular risk factors seem to not be able to account for the huge cardiovascular morbidity and mortality in this population group. Oxidative stress is increased in patients with renal impairment as a result of increased oxidant activity and reduced antioxidant capacity, and this is increased in a graded manner with increasing renal dysfunction. Inflammation, which is also present in CKD, further amplifies the oxidant generation process. The two clinical sequelae of oxidative stress are endothelial dysfunction and left ventricular hypertrophy, which have adverse cardiovascular consequences. With our new understanding of oxidative stress, it is now important to assess treatment options that reduce it in the hope that they reverse endothelial dysfunction and left ventricular hypertrophy and the clinical sequelae of these abnormalities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS . Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41 (1): 1–12.

    Article  PubMed  Google Scholar 

  2. Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003.

  3. Foley RN, Parfrey PS, Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112–S119.

    Article  CAS  PubMed  Google Scholar 

  4. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12 (11): 2411–2417.

    CAS  PubMed  Google Scholar 

  5. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58 (1): 353–362.

    Article  CAS  PubMed  Google Scholar 

  6. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C . Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18 (7): 1272–1280.

    Article  CAS  PubMed  Google Scholar 

  7. Seis H . Oxidative stress: introductory remarks. In: Seis H (ed). Oxidative Stress. Academic Press: London, 1985, pp 1–8.

    Google Scholar 

  8. Finkel T, Holbrook NJ . Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408 (6809): 239–247.

    Article  CAS  PubMed  Google Scholar 

  9. Stocker R, Keaney Jr JF . Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84 (4): 1381–1478.

    Article  CAS  PubMed  Google Scholar 

  10. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103 (9): 1282–1288.

    Article  CAS  PubMed  Google Scholar 

  11. Descamps-Latscha B, Drueke T, Witko-Sarsat V . Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dialysis 2001; 14 (3): 193–199.

    Article  CAS  Google Scholar 

  12. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288 (16): 2008–2014.

    Article  CAS  PubMed  Google Scholar 

  13. Cracowski JL, Ormezzano O . Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases. Eur Heart J 2004; 25 (19): 1675–1678.

    Article  CAS  PubMed  Google Scholar 

  14. Tsimikas S . In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008; 101 (10A): 34D–42D.

    Article  CAS  PubMed  Google Scholar 

  15. Givertz MM, Sawyer DB, Colucci WS . Antioxidants and myocardial contractility: illuminating the ‘Dark Side’ of beta-adrenergic receptor activation? Circulation 2001; 103 (6): 782–783.

    Article  CAS  PubMed  Google Scholar 

  16. Becker BN, Himmelfarb J, Henrich WL, Hakim RM . Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8 (3): 475–486.

    CAS  PubMed  Google Scholar 

  17. Tepel M, Echelmeyer M, Orie NN, Zidek W . Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int 2000; 58 (2): 867–872.

    Article  CAS  PubMed  Google Scholar 

  18. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48 (5): 752–760.

    Article  CAS  PubMed  Google Scholar 

  19. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161 (5): 2524–2532.

    CAS  PubMed  Google Scholar 

  20. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66 (5): 1988–1993.

    Article  CAS  PubMed  Google Scholar 

  21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 23–33.

    Article  Google Scholar 

  22. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P . Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 154–160.

    Article  CAS  PubMed  Google Scholar 

  23. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356 (9237): 1213–1218.

    Article  CAS  PubMed  Google Scholar 

  24. Solomon SD, Rice MM, K AJ, Jose P, Domanski M, Sabatine M et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114 (1): 26–31.

    Article  CAS  PubMed  Google Scholar 

  25. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W . The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107 (7): 992–995.

    Article  CAS  PubMed  Google Scholar 

  26. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med 1994; 16 (3): 339–346.

    Article  CAS  PubMed  Google Scholar 

  27. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS . Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995; 41 (8 Pt 1): 1135–1138.

    CAS  PubMed  Google Scholar 

  28. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J . Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; (111): S4–S9.

    Article  CAS  Google Scholar 

  29. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW . Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38 (6): 1408–1413.

    Article  CAS  PubMed  Google Scholar 

  30. Richard MJ, Arnaud J, Jurkovitz C, Hachache T, Meftahi H, Laporte F et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57 (1): 10–15.

    Article  CAS  PubMed  Google Scholar 

  31. Mimic-Oka J, Simic T, Ekmescic V, Dragicevic P . Erythrocyte glutathione peroxidase and superoxide dismutase activities in different stages of chronic renal failure. Clin Nephrol 1995; 44 (1): 44–48.

    CAS  PubMed  Google Scholar 

  32. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK . Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63 (1): 179–185.

    Article  CAS  PubMed  Google Scholar 

  33. Kalantar-Zadeh K, Brennan ML, Hazen SL . Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48 (1): 59–68.

    Article  CAS  PubMed  Google Scholar 

  34. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA . Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. London GM, Drueke TB . Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51 (6): 1678–1695.

    Article  CAS  PubMed  Google Scholar 

  36. Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R . Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 1995; 25 (4): 564–571.

    Article  CAS  PubMed  Google Scholar 

  37. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G . Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46 (3): 869–876.

    Article  CAS  PubMed  Google Scholar 

  38. Widlansky ME, Gokce N, Keaney Jr JF, Vita JA . The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42 (7): 1149–1160.

    Article  CAS  PubMed  Google Scholar 

  39. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (3): 238–248.

    Article  CAS  PubMed  Google Scholar 

  40. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809–2816.

    Article  CAS  PubMed  Google Scholar 

  41. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361 (9374): 2024–2031.

    Article  CAS  PubMed  Google Scholar 

  42. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Br Med J 2008; 336 (7645): 645–651.

    Article  CAS  Google Scholar 

  43. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47 (1): 186–192.

    Article  CAS  PubMed  Google Scholar 

  44. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G . Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46 (2): 320–327.

    Article  PubMed  Google Scholar 

  45. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS . Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34 (4): 379–388.

    Article  CAS  PubMed  Google Scholar 

  46. Takimoto E, Kass DA . Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49 (2): 241–248.

    Article  CAS  PubMed  Google Scholar 

  47. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105 (4): 509–515.

    Article  CAS  PubMed  Google Scholar 

  48. Spinale FG . Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res 2002; 91 (12): 1082–1084.

    Article  CAS  PubMed  Google Scholar 

  49. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM . Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002; 40 (4): 477–484.

    Article  CAS  PubMed  Google Scholar 

  50. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K et al. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 1999; 85 (2): 147–153.

    Article  CAS  PubMed  Google Scholar 

  51. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001; 89 (5): 453–460.

    Article  CAS  PubMed  Google Scholar 

  52. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110 (3): 331–340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111 (8): 1201–1209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93 (7): 1346–1353.

    Article  CAS  PubMed  Google Scholar 

  55. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105 (14): 1656–1662.

    Article  CAS  PubMed  Google Scholar 

  56. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115 (5): 1221–1231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM . Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005; 66 (3): 444–453.

    Article  CAS  PubMed  Google Scholar 

  58. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322 (22): 1561–1566.

    Article  CAS  PubMed  Google Scholar 

  59. Roman MJ, Saba PS, Pini R, Spitzer M, Pickering TG, Rosen S et al. Parallel cardiac and vascular adaptation in hypertension. Circulation 1992; 86 (6): 1909–1918.

    Article  CAS  PubMed  Google Scholar 

  60. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM . Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15 (1): 43–51.

    Article  CAS  PubMed  Google Scholar 

  61. Nakashima Y, Nii T, Ikeda M, Arakawa K . Role of left ventricular regional nonuniformity in hypertensive diastolic dysfunction. J Am Coll Cardiol 1993; 22 (3): 790–795.

    Article  CAS  PubMed  Google Scholar 

  62. Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39 (3): 739–743.

    Article  CAS  PubMed  Google Scholar 

  63. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334 (18): 1145–1149.

    Article  CAS  PubMed  Google Scholar 

  64. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293 (11): 1338–1347.

    Article  PubMed  Google Scholar 

  65. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12 (11): 2312–2317.

    Article  CAS  PubMed  Google Scholar 

  66. Tarng DC, Huang TP, Chen TW, Yang WC . Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int Suppl 1999; 69: S107–S118.

    Article  CAS  PubMed  Google Scholar 

  67. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM . Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11 (3): 539–549.

    CAS  PubMed  Google Scholar 

  68. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I . Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150 (1): 217–224.

    Article  CAS  PubMed  Google Scholar 

  69. Wratten ML, Navino C, Tetta C, Verzetti G . Haemolipodialysis. Blood Purif 1999; 17 (2-3): 127–133.

    Article  CAS  PubMed  Google Scholar 

  70. George J, Carr E, Davies J, Belch JJ, Struthers A . High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114 (23): 2508–2516.

    Article  CAS  PubMed  Google Scholar 

  71. Blau N, Erlandsen H . The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 2004; 82 (2): 101–111.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Sciences, Centre for Cardiovascular and Lung Biology, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

    M P C Kao, D S C Ang, A Pall & A D Struthers

Authors
  1. M P C Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D S C Ang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Pall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A D Struthers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M P C Kao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kao, M., Ang, D., Pall, A. et al. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24, 1–8 (2010). https://doi.org/10.1038/jhh.2009.70

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2009.70

Keywords

This article is cited by

Search

Advanced search

Quick links